Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer

NCT07068763 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

RADIATION: Lymph-node-sparing short-course radiotherapy
DRUG: Capecitabine
DRUG: PD-1/CTLA-4 inhibitor (Aiparolitoworixureli injection)

Sponsor

Sir Run Run Shaw Hospital